

# Exosome-Based Therapy for Chronic Kidney Disease: Preclinical and IND-Enabling Studies

ILIAS Biologics Inc.



OTHERS	Preclinical
Product Type	Other-Bio.
Indication	Chronic Kidney Disease(CKD)
Target	Major transcriptional regulator of inflammatory responses
MoA(Mechanism of Action)	The exosome is loaded with a therapeutic protein that inhibits a key transcriptional regulator involved in inflammation. By suppressing this factor, it downregulates the expression of inflammation-related genes and cytokines, thereby effectively modulating the inflammatory response.
Competitiveness	This exosome-based therapeutic represents a breakthrough in the treatment of inflammatory diseases, distinguished by its superior biocompatibility and a precise, well-defined mechanism targeting key transcriptional regulators of inflammation. By selectively modulating inflammation-related transcriptional signaling pathways, it effectively minimizes off-target effects and significantly reduces the risk of systemic side effects. Its robust and stable delivery of the therapeutic payload directly into target cells enhances both anti-inflammatory potency and safety, establishing it as a highly differentiated and competitive candidate in the field of inflammation therapy.
Development Stage	Preclinical
Route of Administration	Intravenous injection

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*